These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Observational Cohort Study of Patients With Metastatic Colorectal Cancer Initiating Chemotherapy in Combination With Bevacizumab (CONCERT). Bennouna J; Phelip JM; André T; Asselain B; Sébastien Koné ; Ducreux M Clin Colorectal Cancer; 2017 Jun; 16(2):129-140.e4. PubMed ID: 28277294 [TBL] [Abstract][Full Text] [Related]
3. Real-world first-line treatment of patients with BRAF Martinelli E; Cremolini C; Mazard T; Vidal J; Virchow I; Tougeron D; Cuyle PJ; Chibaudel B; Kim S; Ghanem I; Asselain B; Castagné C; Zkik A; Khan S; Arnold D ESMO Open; 2022 Dec; 7(6):100603. PubMed ID: 36368253 [TBL] [Abstract][Full Text] [Related]
4. Real-World Activity and Safety of Trifluridine-Tipiracil Plus Bevacizumab Therapy in Patients with Refractory Metastatic Colorectal Cancer. Arrichiello G; Perrone A; Napolitano S; Martini G; De Falco V; Incoronato P; Laterza MM; Facchini G; Famiglietti V; Nacca V; Paragliola F; Napolitano R; Suarato G; Nicastro A; Martinelli E; Ciardiello D; Ciardiello F; Troiani T Target Oncol; 2022 Nov; 17(6):635-642. PubMed ID: 36239883 [TBL] [Abstract][Full Text] [Related]
5. The 'real-life' impact of adding bevacizumab to first-line therapy in metastatic colorectal cancer patients: a large Israeli retrospective cohort study. Hammerman A; Greenberg-Dotan S; Battat E; Feldhamer I; Bitterman H; Brenner B Acta Oncol; 2015 Feb; 54(2):164-70. PubMed ID: 25350524 [TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of bevacizumab plus capecitabine and irinotecan regimen for metastatic colorectal cancer. Degirmenci M; Karaca B; Gorumlu G; Durusoy R; Demir Piskin G; Bozkurt MT; Cirak Y; Tunali D; Karabulut B; Sanli UA; Uslu R Med Oncol; 2010 Sep; 27(3):585-91. PubMed ID: 19526201 [TBL] [Abstract][Full Text] [Related]
7. Assessment of Capecitabine and Bevacizumab With or Without Atezolizumab for the Treatment of Refractory Metastatic Colorectal Cancer: A Randomized Clinical Trial. Mettu NB; Ou FS; Zemla TJ; Halfdanarson TR; Lenz HJ; Breakstone RA; Boland PM; Crysler OV; Wu C; Nixon AB; Bolch E; Niedzwiecki D; Elsing A; Hurwitz HI; Fakih MG; Bekaii-Saab T JAMA Netw Open; 2022 Feb; 5(2):e2149040. PubMed ID: 35179586 [TBL] [Abstract][Full Text] [Related]
8. Rate of Curative Surgery in Real-world Patients with Unresectable Metastatic Colorectal Cancer Treated with FOLFOXIRI ± Bevacizumab: A Western Canadian Province Experience. Bhatti T; Moser M; Tan KT; Chalchal H; Souied O; Le D; Shaw J; Zaidi A; Gill D; Ahmed S J Gastrointest Cancer; 2022 Jun; 53(2):427-433. PubMed ID: 33779898 [TBL] [Abstract][Full Text] [Related]
9. ACORN: Observational Study of Bevacizumab in Combination With First-Line Chemotherapy for Treatment of Metastatic Colorectal Cancer in the UK. Khakoo S; Chau I; Pedley I; Ellis R; Steward W; Harrison M; Baijal S; Tahir S; Ross P; Raouf S; Ograbek A; Cunningham D; Clin Colorectal Cancer; 2019 Dec; 18(4):280-291.e5. PubMed ID: 31451367 [TBL] [Abstract][Full Text] [Related]
10. Randomized Phase II Trial of CapOX plus Bevacizumab and CapIRI plus Bevacizumab as First-Line Treatment for Japanese Patients with Metastatic Colorectal Cancer (CCOG-1201 Study). Nakayama G; Mitsuma A; Sunagawa Y; Ishigure K; Yokoyama H; Matsui T; Nakayama H; Nakata K; Ishiyama A; Asada T; Umeda S; Ezaka K; Hattori N; Takami H; Kobayashi D; Tanaka C; Kanda M; Yamada S; Koike M; Fujiwara M; Fujii T; Murotani K; Ando Y; Kodera Y Oncologist; 2018 Aug; 23(8):919-927. PubMed ID: 30049885 [TBL] [Abstract][Full Text] [Related]
11. Impact of Primary Tumor Location on First-line Bevacizumab or Cetuximab in Metastatic Colorectal Cancer. Snyder M; Bottiglieri S; Almhanna K Rev Recent Clin Trials; 2018; 13(2):139-149. PubMed ID: 29595113 [TBL] [Abstract][Full Text] [Related]
13. Treatment patterns and clinical outcomes in patients with metastatic colorectal cancer initially treated with FOLFOX-bevacizumab or FOLFIRI-bevacizumab: results from ARIES, a bevacizumab observational cohort study. Bendell JC; Bekaii-Saab TS; Cohn AL; Hurwitz HI; Kozloff M; Tezcan H; Roach N; Mun Y; Fish S; Flick ED; Dalal D; Grothey A Oncologist; 2012; 17(12):1486-95. PubMed ID: 23015662 [TBL] [Abstract][Full Text] [Related]
14. Sequential Treatment with Bevacizumab and Aflibercept for Metastatic Colorectal Cancer in Real-World Clinical Practice. Buchler T; Kiss I; Hornova J; Fiala O; Wiesnerova M; Svoboda M; Silar J; Kopeckova K; Poprach A; Finek J; Petruzelka L; Melichar B Target Oncol; 2020 Apr; 15(2):193-201. PubMed ID: 32052341 [TBL] [Abstract][Full Text] [Related]
15. Phase I/II trial of capecitabine, oxaliplatin, and irinotecan in combination with bevacizumab in first line treatment of metastatic colorectal cancer. Bazarbashi S; Aljubran A; Alzahrani A; Mohieldin A; Soudy H; Shoukri M Cancer Med; 2015 Oct; 4(10):1505-13. PubMed ID: 26207614 [TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of irinotecan, oxaliplatin, and capecitabine (XELOXIRI) regimen with or without targeted drugs in patients with metastatic colorectal cancer: a retrospective cohort study. Liu X; Ou K; Ma X; Gao L; Wang Q; Zhang H; Yang L BMC Cancer; 2022 Jul; 22(1):807. PubMed ID: 35864467 [TBL] [Abstract][Full Text] [Related]
17. Safety and effectiveness of bevacizumab treatment for metastatic colorectal cancer: final results from the Avastin(®) Registry - Investigation of Effectiveness and Safety (ARIES) observational cohort study. Hurwitz HI; Bekaii-Saab TS; Bendell JC; Cohn AL; Kozloff M; Roach N; Mun Y; Fish S; Flick ED; Grothey A; Clin Oncol (R Coll Radiol); 2014 Jun; 26(6):323-32. PubMed ID: 24686090 [TBL] [Abstract][Full Text] [Related]
18. Clinical outcomes associated with bevacizumab-containing treatment of metastatic colorectal cancer: the BRiTE observational cohort study. Kozloff M; Yood MU; Berlin J; Flynn PJ; Kabbinavar FF; Purdie DM; Ashby MA; Dong W; Sugrue MM; Grothey A; Oncologist; 2009 Sep; 14(9):862-70. PubMed ID: 19726453 [TBL] [Abstract][Full Text] [Related]
19. Bevacizumab with 5-fluorouracil, leucovorin, and oxaliplatin versus bevacizumab with capecitabine and oxaliplatin for metastatic colorectal carcinoma: results of a large registry-based cohort analysis. Buchler T; Pavlik T; Melichar B; Bortlicek Z; Usiakova Z; Dusek L; Kiss I; Kohoutek M; Benesova V; Vyzula R; Abrahamova J; Obermannova R BMC Cancer; 2014 May; 14():323. PubMed ID: 24884897 [TBL] [Abstract][Full Text] [Related]
20. Efficacy and Safety of Bevacizumab Combined With First-Line Chemotherapy in Elderly (≥75 Years) Patients With Metastatic Colorectal Cancer: A Real-World Study. François E; Mineur L; Deplanque G; Laplaige P; Smith D; Gourgou S; Tanang A; Ionescu-Goga M; Veerabudun K; Lelarge Y; Kim S; Rollot F Clin Colorectal Cancer; 2020 Sep; 19(3):e100-e109. PubMed ID: 32299778 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]